Doximity insider plans 5,000-share sale on NYSE for $354,200
Rhea-AI Filing Summary
Doximity, Inc. (DOCS) insider filing notifies a proposed sale of 5,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $354,200.00, scheduled for 10/10/2025 on the NYSE. The shares were acquired the same day by stock option exercise and paid in cash. The filing also discloses three earlier sales by the same seller totaling 15,000 shares in 07/11/2025, 08/08/2025, and 09/12/2025 with gross proceeds of $300,200.00, $315,000.00, and $352,500.00 respectively.
The signer affirms they are unaware of undisclosed material adverse information and, by submitting Form 144, is complying with Rule 144 notification requirements for proposed resale of restricted or control securities.
Positive
- Timely compliance with Rule 144 by notifying a proposed sale of 5,000 shares
- Full disclosure of acquisition method (stock option exercise) and cash payment
- Broker and exchange identified (Morgan Stanley Smith Barney; NYSE) enabling transparent execution
Negative
- Ongoing insider selling evidenced by 15,000 shares sold in the prior three months
- Concentrated short-term disposals may signal continued insider liquidity needs over recent months
Insights
Insider exercised options and plans a sale of 5,000 shares on 10/10/2025.
The filing shows the 5,000 shares were acquired on 10/10/2025 via a stock option exercise with cash payment and are scheduled for sale through Morgan Stanley Smith Barney on the NYSE for an aggregate value of $354,200. This is routine for option holders who exercise and promptly sell to cover tax and cost basis.
Recent prior disposals total 15,000 shares across three dates in 07/11/2025, 08/08/2025, and 09/12/2025, indicating ongoing vesting-related or liquidity-driven sales. Monitor short-term insider liquidity patterns over the next 30-90 days for additional filings.
Form 144 is a procedural disclosure to satisfy Rule 144 resale notice requirements.
The filer affirms the absence of undisclosed material adverse information and provides broker, share count, and aggregate value details required for compliance. The schedule and broker details (Morgan Stanley Smith Barney) align with standard resale channels for registered securities on the NYSE.
Watch for any related Form 4 or amended Form 144s within several days that would confirm execution or changes to the proposed sale.
FAQ
What does the Form 144 filed for DOCS on 10/10/2025 disclose?
Does this Form 144 confirm the sale has occurred?